Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma (clinicaltrials.gov) - Oct 1, 2026 - P1 | N=42 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Nov 2028 ➔ Aug 2027 | Trial primary completion date: Nov 2028 ➔ Aug 2027
Trial completion date • Trial primary completion date • Brain Cancer • Glioblastoma • Oncology • Solid Tumor
|